Varenicline Observational Investigation In The Cessation of Smoking (CHOICES)

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00669240
First received: April 25, 2008
Last updated: August 2, 2010
Last verified: August 2010
  Purpose

The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support "Life REWARDS"TM. This is a non-interventional study.


Condition Intervention
Smoking Cessation
Drug: Varenicline

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Champix Observational Investigation In The Cessation of Smoking

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of Participants With Non-serious Adverse Events (AEs) or Serious Adverse Events (SAEs) [ Time Frame: Baseline through Week 12 or Week 24 ] [ Designated as safety issue: Yes ]
    Non-serious AEs are any untoward medical occurrence in a clinical investigation (subject administered a product or medical device) observed or volunteered through 7 days after the last dose of study drug regardless of suspected causal relationship; SAEs are any untoward medical occurrence that results in death; is life-threatening; requires hospitalization or prolongation of hospitalization; results in disability or incapacity; congenital anomaly or birth defect observed or volunteered through 28 days after the last dose of study drug, regardless of suspected causal relationship.


Secondary Outcome Measures:
  • Number of Participants Whose Smoking Status Was Known at the End of 12 Weeks [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Number of participants who were determined to be a responder or a non-responder at the specified time point. (Responders are participants who answered "no" to both of the following 2 questions, and non-responders are participants who answered "yes" to at least 1 of the following 2 questions, on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?)

  • Number of Participants in Belgium Whose Smoking Status Was Known at the End of 12 Weeks and 24 Weeks [ Time Frame: Week 12 and Week 24 ] [ Designated as safety issue: No ]
    Number of participants in Belgium who were determined to be a responder or a non-responder at the specified time point. (Responders are participants who answered "no" to both of the following 2 questions, and non-responders are participants who answered "yes" to at least 1 of the following 2 questions, on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?)

  • Number of Treatment Responders at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Responders are participants who answered "no" to both of the following 2 questions on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?

  • Number of Treatment Responders in Belgium at Week 12 and at Week 24 [ Time Frame: Week 12 and Week 24 ] [ Designated as safety issue: No ]
    Responders are participants who answered "no" to both of the following 2 questions on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?

  • Number of Participants With Smoking Cessation Assessments at Weekly Intervals From Week 3 Through Week 11 [ Time Frame: Weeks 3, 4, 5, 6, 7, 8, 9, 10, and 11 ] [ Designated as safety issue: No ]
    Assessment of smoking cessation (ie, not a single puff) in previous 7 days, at time points of routine review of patients per local clinical practice.

  • Number of Treatment Responders at Weekly Intervals From Week 3 Through Week 11 [ Time Frame: Weeks 3, 4, 5, 6, 7, 8, 9, 10, and 11 ] [ Designated as safety issue: No ]
    Responders are participants who answered "no" to the following 2 questions: 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days? Assessment conducted at specified time points only when usual for the local clinical practice.

  • Number of Participants for Whom a Maintenance Period of Varenicline Was Prescribed at the End of Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    A maintenance period was an additional period of varenicline treatment that could be prescribed at Week 12 by the attending primary care physician in routine clinical practice

  • Number of Participants Who Received Varenicline, by Duration of Treatment in Days [ Time Frame: Baseline through Week 12 or Week 24 ] [ Designated as safety issue: Yes ]
  • Number of Participants Who Registered With LifeREWARDS On-line Behavioral Support Program [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Number of participants who answered 'yes' to the question "Did you register with LifeREWARDS?" (LifeREWARDS not available in Greece.)

  • Minnesota Nicotine Withdrawal Scale (MNWS) Subscale Scores for Participants in Belgium [ Time Frame: Week 7 and Week 13 or 14 (Week 13/14) ] [ Designated as safety issue: No ]
    Self-administered rating of intensity of nicotine withdrawal symptoms over past 24 hours; consists of 9 questions (urge to smoke, depressed mood, irritability, anxiety, difficulty concentrating, restlessness, increased appetite, difficulty going to sleep, difficulty staying asleep), each rated 0-4 (0=not at all, 1=slight, 2=moderate, 3=quite a bit, 4=extreme). Subscales: Negative affect domain (average of items 2-5); Insomnia domain (average of items 8 and 9); Urge to smoke (item 1); Restlessness (item 6); Increased appetite (item 7). Range 0-4 (higher score=greater intensity of symptoms)


Enrollment: 567
Study Start Date: November 2007
Study Completion Date: August 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Not Specified
Patients prescribed varenicline in a non interventional manner.
Drug: Varenicline
According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
Other Name: Champix, Chantix, CP-526,555

Detailed Description:

Sampling Method Details: Patients as they come to surgeries for smoking cessation treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes. The patients must be willing to make an attempt to stop smoking.

All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.

Criteria

Inclusion Criteria:

  • The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes.
  • The patients must be willing to make an attempt to stop smoking.

Exclusion Criteria:

  • All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00669240

  Show 52 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00669240     History of Changes
Other Study ID Numbers: A3051085
Study First Received: April 25, 2008
Results First Received: June 7, 2010
Last Updated: August 2, 2010
Health Authority: Greece: Ethics Committee

Additional relevant MeSH terms:
Varenicline
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 14, 2014